Astellas Pharma (TSE:4503) 3-Year Revenue Growth Rate : 9.80% (As of Dec. 2024)

View and export this data going back to 1949. Start your Free Trial

What is Astellas Pharma 3-Year Revenue Growth Rate?

Astellas Pharma's Revenue per Share for the three months ended in Dec. 2024 was 円289.07.

During the past 12 months, Astellas Pharma's average Revenue per Share Growth Rate was 21.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 9.80% per year. During the past 5 years, the average Revenue per Share Growth Rate was 5.80% per year. During the past 10 years, the average Revenue per Share Growth Rate was 4.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Astellas Pharma was 75.10% per year. The lowest was -36.10% per year. And the median was 6.65% per year.

Competitive Comparison of Astellas Pharma's 3-Year Revenue Growth Rate

For the Drug Manufacturers - General subindustry, Astellas Pharma's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Astellas Pharma's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's 3-Year Revenue Growth Rate falls into.

Astellas Pharma 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Astellas Pharma (TSE:4503) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Astellas Pharma 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Astellas Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (TSE:4503) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

ALPMY:USA ALPMF:USA YPH:Germany

Address

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website

http://www.astellas.com

Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

Astellas Pharma Headlines

No Headlines